STATE BOARD OF HIGHER EDUCATION'S RESEARCH COMMITTEE FEBRUARY 17, 2021


# SANFORD RESEARCH INNOVATING HEALTH CARE THROUGH CUTTING EDGE SCIENCE

#### **OVERARCHING STRATEGY AND GOALS**

- BUILD INFRASTRUCTURE CAPACITY TO CONDUCT VISIONARY RESEARCH WITH A FOCUS ON HEALTH IMPACT
- LEAD IN PROVIDING PATIENT FACING CLINICAL RESEARCH
- DEVELOP INNOVATIVE PROGRAMS INTEGRATING RESEARCH INTO HEALTHCARE
- CONTINUE DEVELOPMENT OF HUMAN CAPITAL DEDICATED TO RESEARCH AND SCIENTIFIC ADVANCEMENT



## SANFORD HEALTH INTEGRATED HEALTH SYSTEM WITH RESEARCH FOUNDATION



	Scientists	46	New scientists supported by COBREs		
	Physicians	189	CBR, Hybrid positions, Invest. Initiated studies		
	Staff	234	Clinical 44%, Basic 34%, CBR 6%, Admin/Animal 13%		
	Publications	2923	Lifetime publications of SR scientists. $88/153$ in 2019		
	Major Awards	3 COBRES DaCCoTA NCORP 5 R Awards	SR maxed out on CoBRE awards. Replace as move into Phase 3. Add COBRE in CBR and R01s.  Augment Govt grants with commercial.		
	Treatment Approvals	>15 in past 5 yrs.	Oncology and Gene Therapy		
	Clinical Trials	>300 Active	Moved from predominantly Oncology (>60%) to 57% non-oncology		
	Clinical Trial Accruals	>3600 in 2019	Over 12,000 Sanford patients currently on a clinical trial		

## SANFORD RESEARCH - 2020

Specialty Associated Working Group	SPORT	GOST	IGR	Diabetes	CV	WIPF	
Specialties	<ul> <li>Sports Medicine</li> <li>Podiatry</li> <li>Orthopedics</li> <li>Regen Medicine</li> <li>Ortho Trauma</li> </ul>	<ul> <li>GI</li> <li>Ophthalmology</li> <li>Surgery</li> <li>Trauma</li> <li>Neurology</li> </ul>	<ul> <li>Imagenetics</li> <li>Genetics</li> <li>Rare Diseases</li> <li>Pop Health</li> <li>Outcomes</li> <li>Behavioral Health</li> </ul>	<ul><li>T1 Diabetes</li><li>T2 Diabetes</li><li>Endocrinology</li></ul>	<ul> <li>Cardiology</li> <li>Interv. Radiology</li> <li>Vascular</li> </ul>	<ul> <li>Women's</li> <li>IM/ID</li> <li>Pediatrics</li> <li>Family Medicine</li> <li>Nephrology</li> <li>Cystic Fibrosis</li> </ul>	
<b>Physician Lead</b> (Currently Active Pls)	Dr. Noonan Dr. Piatt	Dr. Drofa Dr. Timmerman	Dr. Wonderlich Dr. Hajek	Dr. Griffin Dr. Luis Casas	Dr. Kelly Dr. Haldis Dr. Stys	Dr. Benson Dr. Landeen Dr. Wallace	
Research Support	Directors/PMs						
Executive Leads	Dr. Garcia	Dr. Garcia	Dr. Pearce Dr. Suttle	Dr. Wilcox	Dr. Cauwels	Dr. Suttle	
HSD Leadership	Executive Directors and Clinic Directors as applicable						

## RESEARCH RESPONSE – COVID-19

### BASIC/TRANSLATIONAL

### CLINICAL

#### **BEHAVIORAL**

BIO-ID COVID-19 VIRUS CHARACTERIZATION FORMED COVID SPECIALTY ASSOCIATED WORKING GROUP (SAWG)

BEHAVIORAL HEALTHCARE FOR HEALTHCARE PROFESSIONALS

LAB SUPPORT FOR COVID TESTING AND SERUM TESTING

EXPANDED TREATMENT OPTIONS WITH CLINICAL TRIALS ACROSS DISEASE SPECTRUM

BEHAVIORAL HEALTH BRIDGE PROJECT WITH UND (RURAL MENTAL HEALTH)

CHARACTERIZATION OF ANTIBODY
RESPONSE WITH HEALTHCARE WORKER
ANTIBODY STUDY

ADAPTIVE COVID-19 TRIAL TO RAPIDLY TEST THERAPY OPTIONS AND COMBINATIONS – INPATIENT AND OUTPATIENT STUDIES

RESILIENCE TRAINING FOR HOSPITAL WORKERS

BIOSTATS CORE SUPPORT (REGISTRY/PATIENT CARE DATA) CELLULAR THERAPY CLINICAL TRIALS – FIRST IN NATION

OUTPATIENT ANTIBODY INFUSION CREATION – OPEN IN TWO WEEKS, TREATED 1800+ TO DATE

